Biocon's Pebrilzo becomes first biosimilar to get EMA CHMP nod via tailored approach
- Biocon's Pebrilzo receives EMA CHMP positive opinion for marketing authorisation
- It is the first monoclonal antibody biosimilar approved under the tailored clinical development approach
- Product treats HER2-positive breast cancer in neoadjuvant, adjuvant, and metastatic settings
- European Commission to conduct final review before EU marketing authorisation is granted
*this image is generated using AI for illustrative purposes only.
Biocon Limited announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending marketing authorisation for its Pertuzumab biosimilar, Pebrilzo.
The product is indicated for treating HER2-positive breast cancer across multiple disease stages. The opinion follows a review of the application submitted by Biocon Biologics Ireland Limited, an indirect wholly-owned subsidiary of Biocon Biologics Limited.
Regulatory Milestone
The CHMP opinion marks the first time a monoclonal antibody biosimilar has received such a recommendation under the EMA's tailored clinical development approach. Shreehas Tambe, CEO and Managing Director of Biocon, stated that this reflects greater regulatory confidence in advanced analytical and clinical pharmacology evidence to establish biosimilarity.
The European Commission will now proceed with the final review. Until marketing authorisation is granted by the Commission, the product is not authorised for use in the European Union.
Product Indications
Pebrilzo contains Pertuzumab, a monoclonal antibody that binds to the human epidermal growth factor receptor 2 (HER2). It inhibits the proliferation of tumour cells that overexpress HER2.
| Indication Type | Patient Profile | Combination Therapy |
|---|---|---|
| Neoadjuvant | Adult patients with HER2-positive locally advanced, inflammatory, or early-stage breast cancer at high risk of recurrence | Trastuzumab and chemotherapy |
| Adjuvant | Adult patients with HER2-positive early breast cancer at high risk of recurrence | Trastuzumab and chemotherapy |
| Metastatic | Adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer without prior anti-HER2 therapy | Trastuzumab and Docetaxel |
Extensive structural and functional analytical characterization, along with comparative clinical pharmacokinetic data, demonstrated that Pebrilzo is highly similar to the reference biologic. The company stated there are no clinically meaningful differences in quality, safety, or efficacy.
What the Numbers Show
The approval pathway leverages a tailored clinical development approach rather than traditional extensive clinical trials. This regulatory shift indicates that robust analytical and pharmacokinetic data alone can suffice for establishing biosimilarity for certain monoclonal antibodies, potentially reducing development timelines and costs for future assets in Biocon's pipeline of 20+ biosimilar candidates.
Historical Stock Returns for Biocon
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +1.01% | -0.45% | -6.85% | +1.65% | +5.56% | 0.0% |
How might the EMA's acceptance of a tailored clinical development approach for Pebrilzo influence the regulatory strategy for Biocon's remaining 20+ biosimilar candidates?
What is the projected timeline for the European Commission's final review, and how could potential delays impact Biocon's market entry strategy in the EU?
How will the launch of Pebrilzo affect the pricing dynamics and market share of originator Pertuzumab in the European oncology sector?
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
